Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis
Launched by DOW PHARMACEUTICAL SCIENCES · Nov 3, 2009
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinically diagnosed onychomycosis of the target nail
- • Presence of mild to moderate onychomycosis, defined as 20 - 50% of the area of the target nail being clinically affected
- • Has a positive KOH examination from the target nail
- • Has a positive dermatophyte culture from the target nail
- Exclusion Criteria:
- • Presence of any disease or condition that might cause nail abnormalities or may interfere with the evaluation of the study drug
- • Use of any systemic antifungal therapy within 4 weeks prior to the Screening visit or non-responsive to systemic antifungal therapy for onychomycosis
- • Use of any prescription or over-the-counter topical antifungal therapy for the toenails within 4 weeks prior to the Screening visit
- • Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period
About Dow Pharmaceutical Sciences
Dow Pharmaceutical Sciences is a leading organization specializing in the development and manufacturing of innovative drug delivery systems and pharmaceutical formulations. With a strong emphasis on scientific research and technological advancement, the company collaborates with pharmaceutical and biotechnology firms to enhance therapeutic efficacy and patient compliance. Dow Pharmaceutical Sciences is committed to advancing healthcare solutions through rigorous clinical trials and a comprehensive understanding of pharmacokinetics, formulation development, and regulatory processes, ultimately aiming to improve patient outcomes and streamline the path to market for new therapeutics.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
San Francisco, California, United States
Longmont, Colorado, United States
Hershey, Pennsylvania, United States
Dallas, Texas, United States
Birmingham, Alabama, United States
Goodlettsville, Tennessee, United States
Norfolk, Virginia, United States
San Diego, California, United States
Louisville, Kentucky, United States
Phoenix, Arizona, United States
Lynchburg, Virginia, United States
New Haven, Connecticut, United States
Boise, Idaho, United States
Edmonton, Alberta, Canada
North Bay, Ontario, Canada
Clinton Township, Michigan, United States
Barrie, Ontario, Canada
Windsor, Ontario, Canada
Milwaukee, Wisconsin, United States
South Euclid, Ohio, United States
Calgary, Alberta, Canada
Miami, Florida, United States
Albuquerque, New Mexico, United States
Evansville, Indiana, United States
Snellville, Georgia, United States
Salt Lake City, Utah, United States
New London, Ontario, Canada
Ormond Beach, Florida, United States
Philadelphia, Pennsylvania, United States
College Station, Texas, United States
Nagasaki, , Japan
San Diego, California, United States
Altamonte Springs, Florida, United States
Augusta, Georgia, United States
New Hyde Park, New York, United States
Cinncinati, Ohio, United States
Portland, Oregon, United States
Greenville, South Carolina, United States
Austin, Texas, United States
San Antonio, Texas, United States
Québec, Quebec, Canada
Dazaifu, Fukuoka, Japan
Itoshima, Fukuoka, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Kawasaki, Kanagawa, Japan
Ginowan, Okinawa, Japan
Naha, Okinawa, Japan
Nakagami, Okinawa, Japan
Urasoe, Okinawa, Japan
Kawaguchi, Saitama, Japan
Nakano Ku, Tokyo, Japan
Nakano Ku, Tokyo, Japan
Setagaya Ku, Tokyo, Japan
Setagaya Ku, Tokyo, Japan
Shinagawa Ku, Tokyo, Japan
Shinagawa Ku, Tokyo, Japan
Fukuoka, , Japan
Fukuoka, , Japan
Fukuoka, , Japan
Fukuoka, , Japan
Fukuoka, , Japan
Okinawa, , Japan
Okinawa, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials